Skip to content
Bored Studies
RecruitingPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Eli Lilly and Company · NCT07369011

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
800
US sites recruiting
23
Study start
February 10, 2026
Record last updated
October 8, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or unwilling to use Positive Airway Pressure (PAP) therapy and study YSA2 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study.

Participants will be assigned to the Intervention-Specific Appendix (ISA) that reflects their current PAP usage. Participation in the study will last about 76 weeks.

Being studied: Eloralintide; Placebo

Conditions: Sleep Apnea, Obstructive; Obesity; Overweight

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Confirmed history of moderate-to-severe OSA
  • Have an AHI ≥ 15 on polysomnography (PSG) as part of the study at screening
  • Have a BMI ≥27 kg/m2 at screening
  • Have a stable body weight (\<5% body weight change) for 90 days prior to screening
  • Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight

For YSA1 Participants:

  • Are unable or unwilling to use PAP therapy

For YSA2 Participants:

  • Have been on PAP therapy for at least three consecutive months prior to screening and plan to continue PAP therapy during the study

Exclusion Criteria

  • Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
  • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
  • Any previous or planned surgery for sleep apnea or major ear, nose or throat surgery that still may affect breathing at time of screening
  • Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
  • Have had within 90 days prior to screening:
  • acute myocardial infarction
  • cerebrovascular accident (stroke)
  • coronary artery revascularization
  • unstable angina, or
  • hospitalization due to congestive heart failure
  • Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
  • Have taken medications or alternative remedies intended for weight loss within 90 days of screening

Recruiting US locations

  • Cullman Clinical Trials

    Cullman, AL 35055

    Site contact: 256-708-2826

  • Ark Clinical Research

    Long Beach, CA 90815

    Site contact: 562-997-1000

  • Collaborative Neuroscience Research, LLC

    Los Alamitos, CA 90720

    Site contact: 714-799-7799

  • Artemis Institute for Clinical Research

    Riverside, CA 92503

    Site contact: 951-374-1190

  • Care Access - Aurora

    Aurora, CO 80012

    Site contact: 720-368-4865

  • Flourish Research - Miami, LLC

    Miami, FL 33135

    Site contact: 305-631-6704

  • PharmaDev Clinical Research Institute, LLC

    Miami, FL 33176

    Site contact: 305-420-5636

  • Emerald Coast Neurology - Airport Boulevard

    Pensacola, FL 32504

    Site contact: 850-438-1136

  • Teak Research Consults

    Lawrenceville, GA 30043

    Site contact: Kamar Alabi

  • EBGS Clinical Research Center

    Snellville, GA 30078

    Site contact: 770-729-4517

  • Care Access - Shreveport 2

    Shreveport, LA 71105

    Site contact: 318-209-3290

  • Flourish Research - Bowie

    Bowie, MD 20715

    Site contact: 410-824-1342

  • Revive Research Institute, Inc.

    Southfield, MI 48075

    Site contact: 248-829-3103

  • Headlands Research-Twin Cities

    Maplewood, MN 55109

    Site contact: Charlene McEvoy

  • Clayton Sleep Institute - St. Louis - Tesson Ferry Road

    St Louis, MO 63123

    Site contact: 314-645-6005

  • Palm Research Center Tenaya

    Las Vegas, NV 89128

    Site contact: 702-736-5161

  • The Sleep Spot - Maimonides

    Albuquerque, NM 87107

    Site contact: 505-998-7200

  • Rochester Clinical Research - Buffalo

    Buffalo, NY 14127

    Site contact: Rajiv Jain

  • CTI Clinical Research Center

    Cincinnati, OH 45212

    Site contact: 513-721-3868

  • Bogan Sleep Consultants

    Columbia, SC 29201

    Site contact: 803-251-3093

  • FutureSearch Trials of Neurology

    Austin, TX 78731

    Site contact: 512-380-9925

  • Sleep Therapy Research Center

    San Antonio, TX 78229

    Site contact: Nagwa Lamaie

  • Consano Clinical Research, LLC

    Shavano Park, TX 78231

    Site contact: 210-545-4900

Study contacts (from the official record)

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
  • Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
All weight loss studies in Alabama →
A Study of Eloralintide (LY3841136) in Participants With… (NCT07369011) | Bored Studies